Press releaseGlobe Newswire
HUTCHMED (China)
HCM · HONG
$14.36+$0.08 (+0.56%)TodayMarket closed ·
Prev close $14.28
Latest news
- Press releaseGlobe Newswire
HUTCHMED Announces Submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer
- Press releaseGlobe Newswire
HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors
- Press releaseGlobe Newswire
HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026
- News
HUTCHMED (China) Reports H1 2026 Results: Full Earnings Call Transcript
- NewsVandana Singh
Why Is HUTCHMED Stock Soaring Thursday?
- NewsAvi Kapoor
Why Snowflake Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket
- News
HUTCHMED Signs GSK Cancer Drug Deal Worth Up To $1.3B, Gets $110M Upfront
- Press releaseGlobe Newswire
HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy
- NewsVandana Singh
AstraZeneca Shares Dual Oncology Clinical and Regulatory Victories
- Press releaseGlobe Newswire
HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China
- NewsVandana Singh
AstraZeneca Reports Mixed Lung Cancer Trial Outcomes From Three Pivotal Studies
- News
HUTCHMED (China) H1 EPS $0.09 Down From $2.61 YoY, Sales $278.287M Up From $277.677M YoY
- Press releaseGlobe Newswire
HUTCHMED Reports 2026 Interim Results
- NewsVandana Singh
HUTCHMED's Experimental Drug Shows Durable Responses In Advanced Bile Duct Cancer Trial
- News
Earnings Scheduled For March 5, 2026
- News
HUTCHMED (China) FY EPS $2.62 Beats $1.43 Estimate, Sales $548.512M Miss $591.425M Estimate
- Press releaseGlobe Newswire
HUTCHMED Reports 2025 Full Year Results and Business Updates
- News
An Overview of HUTCHMED (China)'s Earnings
- NewsVandana Singh
Positive China Trial Data Moves HUTCHMED Closer To Rare Blood Disorder Drug Filing In 2026
- NewsAvi Kapoor
IBEX, Tesla, IonQ, Warner Bros. Discovery And Other Big Stocks Moving Higher On Friday
- Press releasePRNewswire
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market
- Press releaseGlobe Newswire
HUTCHMED Reports 2025 Interim Results
- NewsAvi Kapoor
Progress Software Posts Upbeat Results, Joins Microvast, PVH And Other Big Stocks Moving Higher On Tuesday
- NewsVandana Singh
Hutchmed's Oncology Revenue Hits $271.5 Million, Rising 65% On Fruzaqla Strength
- Press releaseGlobe Newswire
HUTCHMED Announces US$608 million Divestment of Non-Core Joint Venture
- Press releasePRNewswire
Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer
- Press releasePRNewswire
FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket
- Press releaseGlobe Newswire
HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.